Table 1.
Descriptive analysis of the 300 included patients at baseline
| Variables | Estimates | N | Missing information (N) |
|---|---|---|---|
| Socio-demographic factors | |||
| Age (years), median (IQR) | 40.1 (33-46.5) | 0 | |
| Female, % (95% CI) | 70.3 (65-75) | 211 | 0 |
| Body mass index (kg/m2), median (IQR) | 21.8 (19.3-24.2) | 7 | |
| HIV-related factors | |||
| CD4 (cells/mm3), median (IQR) | 325 (205-502) | 14 | |
| Viral load (log10 copies/ml), median (IQR) | 1.65 (< 1.6-3.1) | 11 | |
| Current use of HAART, % (95% CI) | 69.8 (65.5-75.0) | 205 | 3 |
| Current use of cotrimoxazole, % (95% CI) | 87 (82-90) | 260 | 0 |
| History of tuberculosis, % (95% CI) | 39.2 (33.7-45) | 117 | 2 |
| Kidney risk factors | |||
| History of diabetes, % (95% CI) | 2.0 (0.7-4.3) | 6 | 2 |
| History of hypertension*, % (95% CI) | 2.7 (1.1-5.2) | 8 | 1 |
| Positive hepatitis B serology, % (95% CI) | 5.0 (2.7-8.2) | 14 | 19 |
| Positive Hepatitis C serology, % (95% CI) | 5.3 (3.0-8.6) | 15 | 20 |
| History of aminoglycosides use, % (95% CI) | 8.7 (5.6-12.8) | 23 | 37 |
| History of NSAID use, % (95% CI) | 47.9 (42-54) | 135 | 18 |
| Renal functions | |||
| GFR Cockroft-Gault (ml/min), median (IQR) | 99.7 (79-126) | 0 | |
| GFR MDRD (ml/min/1.73 m2), median (IQR) | 111 (88-138) | 0 | |
IQR, Inter Quartile Range; 95% CI, 95% Confidence Interval; HAART, Highly Active Antiretroviral Therapy; NSAID, Non Steroidal Anti-Inflammatory Drugs; GFR, Glomerular Filtration Rate; MDRD, Modification of Diet in Renal Disease
* TAS > 16 or TAD > 10 at physical assessment or a previous history of hypertension.